Shares of Ocular Therapeutix Inc. (OCUL) tumbled more than 33% in extended trading on Monday after the company announced that its second of two phase III clinical trials evaluating its lead product candidate OTX-DP for the treatment of post-surgical ocular inflammation and pain did not meet the primary efficacy endpoint for inflammatory cells.